1. Prediction of Drug Response in the New Population by Assessing the Susceptibility to Ethnic Differences—Realizable or Hypothetical?

   • Yeong-Liang Lin

   Clinical Trial 30 December 2006 Pages: 1 - 6

2. Pharmacogenomic Testing and Regulation: The Role of Pharmacogenomics in Pharmaceutical Development and the Regulation of Pharmacogenetic Test as in Vitro Diagnostics

   • David Jefferys
   • David Atkins
   • Steven Gutman

   Pharmacogenomics 30 December 2006 Pages: 7 - 13

3. Dialogue between Companies and the EMEA regarding the Centralized Procedure from an Industry’s Point of View

   • Karin Heidenreich

   Regulatory 30 December 2006 Pages: 15 - 21

4. An Overview of the US Regulatory Environment for Drug-Device and Biologic-Device Combination Products

   • Michael R. Hamrell

   Regulatory 30 December 2006 Pages: 23 - 32

5. Good Laboratory Practice (GLP) Regulations: Interpretation Techniques and Review of Selected Compliance Issues

   • Christine S. Lee
   • John Y. Lee

   Regulatory 30 December 2006 Pages: 33 - 38

6. The Drug Information Center Arthritis Project: Providing Patients with Interactive and Reliable Arthritis Internet Education

   • Nicole T. Ansani
   • Bethany A. Fedutes-Henderson
   • Terence W. Starz

   Drug Information 30 December 2006 Pages: 39 - 49

7. A Survey of Drug Information Resources in Alabama Pharmacy Facilities

   • Robert H. Schrimsher
   • Maisha Kelly Freeman
   • Michael Kendrach

   Drug Information 30 December 2006 Pages: 51 - 60

8. Using Patient-Oriented Evidence-Based Information Guides in Practice: The Family Physician and Community Pharmacist Perspective

   • Lisa Dolovich
   • Sheri Burns
   • Jean Gray

   Drug Information 30 December 2006 Pages: 61 - 67

9. Design and Analysis of Dose Escalation Studies to Mitigate Dose-Limiting Adverse Effects

   • Larry Z. Shen
   • Mark S. Fineman
   • Alain Baron

   Statistics 30 December 2006 Pages: 69 - 78

10. Analysis of Adverse Events in the Presence of Discontinuations

    • Gerd Rosenkranz

    Pharmacovigilance/Adverse Events 30 December 2006 Pages: 79 - 87

11. Detecting Rare Adverse Events in Postmarketing Studies: Sample Size Considerations

    • Yu-te Wu
    • Robert W. Makuch

    Pharmacovigilance/Adverse Events 30 December 2006 Pages: 89 - 98

12. Multivariate Analysis of Adverse Events

    • Robert Goldberg-Alberts
    • Sam Page

    Pharmacovigilance/Adverse Events 30 December 2006 Pages: 99 - 110

13. Patient-Reported Pain is Central to OMERACT Rheumatology Core Measurement Sets

    • Vivian Robinson
    • Maarten Boers
    • George A. Wells

    Pharmacovigilance/Adverse Events 30 December 2006 Pages: 111 - 116

14. Development of a Facts Database for Evidence-Based Adverse Reaction Diagnosis

    • Fumiko Ohtsu
    • Reiko Yano
    • Kazuhiro Inagaki

    Pharmacovigilance/Adverse Events 30 December 2006 Pages: 117 - 124

15. 2006 EuroMeeting Student Poster Abstracts

    Abstract 30 December 2006 Pages: 125 - 130